Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug ...
Intellia Therapeutics is downgraded to Sell due to safety concerns and weak commercial prospects in ATTR and HAE. NTLA's ATTR program faces a clinical hold after a Hy’s-law-threshold liver event, with ...
Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...
Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 44% to $14.34 in early trading Monday. The ...
CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its target price lowered by Chardan Capital from $91.00 to $68.00 in a report published on Friday morning,Benzinga reports. The brokerage ...
Intellia Therapeutics (NASDAQ: NTLA) found out this past week what other genetic medicine developers have learned in recent weeks: Any safety issue that arises in a clinical trial is enough to send ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.99, expectations were $-1.03.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback